Purple BiotechPurple Biotech
  • Home
  • About us
    • Our History
    • Mission
    • Executive Team
    • Board of Directors
  • Pipeline
    • Overview
    • CM24
    • NT219
    • Publications
  • Investors
    • Overview
    • Events
    • Press Releases
    • SEC Filings
    • Shareholders Meetings
    • Email Alerts
    • Corporate Governance
  • Contact us
menu
  • Home
  • About us
  • Pipeline
  • Investors
  • Contact Us
To Top

Category: more about NT-219

Categories

  • Publications
    • CM-24
    • more about CM-24
    • more about NT-219
    • NT-219

Posts

  • Interim Safety and Efficacy Results from a Phase 1 Study of NT219 in Adults with Advanced Solid Tumors
  • Interim Safety and Efficacy Results from a Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
  • IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy
  • A Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors, followed by a Phase 2a study of CM24 in Combination with Nivolumab in NSCLC, and in Combination with Nivolumab and nab-paclitaxel in Pancreatic Cancer
  • A Phase 1 2 Study with Open Label, Dose Escalation Phase Followed by Single Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT 219 Injection Alone and in Combination with Cetuximab in Adults with Advanced Solid Tumors and Head and Neck Cancer
  • Adaptation of Colorectal Cancer Cells to the Brain Microenvironment The Role of IRS2
  • View more: CM-24 references
  • View more: NT-219 References
  • A Phase 1 Open-label Multicenter Single Dose Escalation and Multi-dose Study of a mAb Targeting CEACAM1 in Subjects with Selected Advanced or Recurrent Malignancies
  • NT219, a Novel Dual Inhibitor of STAT3 and IRS1/2, Demonstrates Anti-Tumor Activity With and Without Cetuximab in Pembrolizumab-Resistant Head and Neck Cancer PDX Models

View more: NT-219 References

By yarone
in
more about NT-219
Jan 01, 2021
Download PDF file
Read more
Corporate Headquarters

4 Oppenheimer St.
Science Park, Rehovot
Israel 7670104
Tel : + 972-3-9333121

ir@purple-biotech.com

 

Purple biotech
  • Investors
  • Pipeline
  • About us
  • Contact Us

2021 All Rights Reserved. Created BY ATEAS.BIZ

  • Home
Skip to content
Open toolbar

Accessibility Tools

  • Increase Text
  • Decrease Text
  • Grayscale
  • High Contrast
  • Negative Contrast
  • Light Background
  • Links Underline
  • Readable Font
  • Reset